Compare RJET & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJET | IMMX |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | 8400 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.1M | 784.8M |
| IPO Year | 2009 | 2021 |
| Metric | RJET | IMMX |
|---|---|---|
| Price | $19.56 | $7.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.43 |
| AVG Volume (30 Days) | 59.2K | ★ 1.3M |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.43 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $1,676,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.88 | ★ N/A |
| Revenue Growth | ★ 13.74 | N/A |
| 52 Week Low | $1.33 | $2.85 |
| 52 Week High | $26.70 | $15.10 |
| Indicator | RJET | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 30.35 |
| Support Level | $18.43 | N/A |
| Resistance Level | $19.44 | $9.04 |
| Average True Range (ATR) | 0.81 | 0.54 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 75.68 | 7.80 |
Republic Airways Holdings Inc is a regional airline mainly in North America. The company provides scheduled passenger service through its mainline partnerships with American Airlines, Delta Air Lines, and United Airlines. Republic offers scheduled passenger service on several daily flights to various cities in the United States, Canada, Mexico, and the Caribbean. It exclusively operates the dual-class Embraer E170/175 family of aircraft, and provides its services under the American Eagle, Delta Connection, or United Express brands. The company is organized and operates as one operating and reportable segment: regional airline services.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.